<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TELAPREVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TELAPREVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.125 g every 12 hours, alternatively 750 mg every 8 hours, for duration of treatment consult product literature.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid in moderate to severe impairment.</p>
            </section>
      </section>



      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Anaemia (in combination with ribavirin and peginterferon alfa), anal fissure (in combination with ribavirin and peginterferon alfa), diarrhoea (in combination with ribavirin and peginterferon alfa), eczema (in combination with ribavirin and peginterferon alfa), haemorrhoids (in combination with ribavirin and peginterferon alfa), hyperbilirubinaemia (in combination with ribavirin and peginterferon alfa), hyperuricaemia (in combination with ribavirin and peginterferon alfa), hypokalaemia (in combination with ribavirin and peginterferon alfa), hypothyroidism (in combination with ribavirin and peginterferon alfa), lymphopenia (in combination with ribavirin and peginterferon alfa), nausea (in combination with ribavirin and peginterferon alfa), peripheral oedema (in combination with ribavirin and peginterferon alfa), pruritus (in combination with ribavirin and peginterferon alfa), rash (in combination with ribavirin and peginterferon alfa), syncope (in combination with ribavirin and peginterferon alfa), taste disturbances (in combination with ribavirin and peginterferon alfa), thrombocytopenia (in combination with ribavirin and peginterferon alfa), vomiting (in combination with ribavirin and peginterferon alfa),
              </p>
              <p>
                <strong>uncommon:</strong> Gout (in combination with ribavirin and peginterferon alfa), proctitis (in combination with ribavirin and peginterferon alfa), retinopathy (in combination with ribavirin and peginterferon alfa), urticaria (in combination with ribavirin and peginterferon alfa),
              </p>
              <p>
                <strong>rare:</strong> Stevens-Johnson syndrome (in combination with ribavirin and peginterferon alfa), toxic epidermal necrolysis (in combination with ribavirin and peginterferon alfa),
              </p>
        
        
            <section class="advice">
                <h3>Rash</h3>
              <p>Rash occurs very commonly. If rash mild or moderate, may continue without interruption, but monitor for deterioration. If moderate rash deteriorates, consider permanent discontinuation of telaprevir; if rash does not improve within 7 days of discontinuation, suspend ribavirin. If severe rash or if rash accompanied by blistering or mucosal ulceration, discontinue telaprevir permanently; if rash does not improve within 7 days of discontinuation, consider discontinuation of ribavirin and peginterferon alfa. If serious rash, or if severe rash deteriorates, or if rash accompanied by systemic symptoms, discontinue telaprevir, ribavirin, and peginterferon alfa permanently.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose is more than 6 hours late with the 12 hourly regimen (or more than 4 hours late with the 8 hourly regimen), the missed dose should not be taken and the next dose should be taken at the normal time.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients should be told to seek immediate medical attention if a rash develops or if an existing rash worsens.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA252</h3>
              <p outputclass="title">Telaprevir for chronic hepatitis C infection of genotype 1 (April 2012)</p> <p>Telaprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease: </p> <ul> <li>who have not been treated previously;</li> <li>in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA252">www.nice.org.uk/TA252</xref>
                <a href="http://www.nice.org.uk/TA252" target="_blank">www.nice.org.uk/TA252</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Bradycardia
          </li>
          <li>
            congenital or family history of QT interval prolongation
          </li>
          <li>
            electrolyte disturbances
          </li>
          <li>
            family history of sudden death
          </li>
          <li>
            heart failure with reduced left ventricular ejection fraction
          </li>
          <li>
            hypoalbuminaemia
          </li>
          <li>
            low platelets
          </li>
          <li>
            prolongation of QT interval
          </li>
        </ul>
        <ul>
          <li>
            <p>Not recommended in patients with low platelets or hypoalbuminaemia&#8212;if initiated in these patients monitor closely for signs of infection, worsening liver impairment, and anaemia (increased risk of severe morbidity and mortality).</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Effectiveness of hormonal contraceptives reduced during treatment and for 2 months after stopping telaprevir&#8212;effective non-hormonal methods of contraception necessary during this time.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor full blood count, platelets, electrolytes, serum creatinine, uric acid, and liver and thyroid function tests before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Dispense in original container (contains desiccant).</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TELAPREVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76644"><a href="../medicinalForm/PHP76644.html" data-target="#PHP76644" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
